Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma

Journal of Neuro-Oncology

Volumn 119, Issue 1, 2014, Pages 135-140

  Hamza, Mohamed A ^a,c   Mandel, Jacob J ^a   Conrad, Charles A ^a   Gilbert, Mark R ^a   Yung, W K Alfred ^a   Puduvalli, Vinay K ^b   DeGroot, John F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c OhioHealth   (United States)

Author keywords

Delayed bevacizumab; Early bevacizumab; Recurrent glioblastoma; Survival outcome

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COMPARATIVE STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL FACTOR; THERAPY DELAY; TIME TO TREATMENT; TREATMENT OUTCOME; BRAIN NEOPLASMS; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TIME; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906938309     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1460-z     Document Type: Article

References (21)

1. Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12(1):20-37 (Pubitemid 46143500)
2. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
3. Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11):1131-1138. doi:10.1634/theoncologist.2009-0121.Epub
4. Argirios M, Teri NK (2010) New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. Onco Targets Ther 3:27-38. Published online 2010 June 24
5. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787
6. Ananthnarayan S, Bahng J, Roring J et al (2008) Time course of imaging changes of glioblastoma during extended bevacizumab treatment. J Neurooncol 88:339-347
7. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740. doi:10.1200/JCO.2008.19.8721. Epub 2009 Aug 31
8. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253-1259 (Pubitemid 46424067)
9. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722-4729 (Pubitemid 350086473)
10. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740-745
11. Du R, Lu KV, Petritsch C et al (2008) HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13(3):206-220. doi:10.1016/j.ccr.2008.01.034 (Pubitemid 351318372)
12. Iwamoto FM, Abrey LE, Beal K et al (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73(15):1200-1206. doi:10.1212/WNL.0b013e3181bc0184
13. de Groot JF, Fuller G, Kumar AJ et al (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncology 12(3):233-242. doi:10.1093/neuonc/nop027. Epub 2010 Jan 6
14. Dong J, Grunstein J, Tejada M et al (2004) VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23(14):2800-2810. Epub 2004 Jul 1
15. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592-603. doi:10.1038/nrc2442
16. Piao Y, Liang J, Holmes L et al (2012) Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation and mesenchymal phenotype. Neuro-Oncology 14(11):1379-1392
17. Rubenstein JL, Kim J, Ozawa T et al (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2(4):306-314
18. Wick A, Dorner N, Schafer N et al (2011) Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 69(3):568-592
19. Gilbert MR, Dignam J, Won M et al (2013) RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 31(suppl):abstr 1
20. Henriksson R, Bottomley A, Mason W et al (2013) Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio: a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 31(suppl):abstr 2005
21. Piccioni DE, Selfridge J, Mody RR et al (2014) Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro-oncology. doi:10.1093/neuonc/nou028